Evidence behind this recommendation.
Selected studies from our library that inform the recommendations on this page. Evidence grade shown when available.
Effects of acupuncture and moxibustion on ulcerative colitis: An overview of systematic reviews
“This study analyzed the quality of existing research on acupuncture and moxibustion for ulcerative colitis.”
Acupuncture for gastrointestinal diseases
“This review shows that acupuncture can be a safe and effective option for various diseases of the digestive system, including irritable bowel syndrome, constipation, reflux, and inflammatory dis...”
What Ulcerative Colitis Is
Ulcerative colitis (UC) is a chronic inflammatory bowel disease (IBD) that affects the mucosa of the large intestine in a continuous fashion, always starting in the rectum and potentially extending proximally to involve the entire colon. Unlike Crohn's disease, the inflammation in UC is superficial — restricted to the mucosa and submucosa — and never affects the small intestine in isolation.
In Brazil, the estimated prevalence is 50 to 200 cases per 100,000 inhabitants, with two peaks of incidence: between 15 and 35 years of age (main peak) and between 55 and 65 years. UC affects men and women similarly and is associated with genetic factors (NOD2, IL-23R), environmental factors (microbiome, Westernized diet), and immunological factors (Th1/Th17 dysfunction).
The classic clinical picture includes diarrhea with blood and mucus, fecal urgency, tenesmus, abdominal cramping and, in severe cases, fever, weight loss, and anemia. UC follows a course of flares of activity interspersed with periods of remission. In pancolitis with more than 10 years of evolution, the risk of colorectal carcinoma is elevated, requiring regular endoscopic surveillance.
Psychosocial Impact
Conventional Treatments
UC treatment is escalated according to extent, severity, and response to prior treatment. The goal is to induce and maintain mucosal remission (endoscopic healing), associated with a lower risk of colectomy and colorectal carcinoma.
THERAPEUTIC OPTIONS IN UC
| MEDICATION / INTERVENTION | INDICATION | CONSIDERATIONS |
|---|---|---|
| Mesalazine (5-ASA) | Mild to moderate; maintenance | Gold standard; combined oral + topical |
| Systemic corticosteroids | Induction of remission in flares | Not indicated for maintenance (toxicity) |
| Azathioprine / 6-MP | Maintenance; corticosteroid dependence | 3–6 month latency; monitor blood count |
| Infliximab / Adalimumab | Moderate to severe; 5-ASA failure | Anti-TNF; increased infectious risk |
| Vedolizumab | Moderate to severe; alternative | Anti-integrin; gut-selective action |
| Tofacitinib / Upadacitinib | Moderate to severe; biologic-refractory | Oral JAK inhibitors; monitor thromboembolism |
| Colectomy | Refractory, dysplasia, or megacolon | Curative; total proctocolectomy with ileal pouch |
How Acupuncture Works in Ulcerative Colitis
The action of medical acupuncture in UC involves two main mechanisms: neuroimmune modulation via the cholinergic anti-inflammatory vagal reflex and regulation of the gut-brain axis with direct impact on the inflammatory cytokine profile of the colonic mucosa.
Mechanism of Action in UC
ST36 (Zusanli) Stimulation
Activation of somatic afferents of the lower limb — deep peroneal nerve — with ascending signaling via Th10–L2 and activation of the vagus nerve.
Cholinergic Anti-Inflammatory Reflex
Acetylcholine released by enteric neurons activates α7-nicotinic receptors (α7nAChR) on macrophages of the colonic submucosa, suppressing the pro-inflammatory response.
Inhibition of the NF-κB Pathway
Silencing of the nuclear factor NF-κB → reduction of TNF-α, IL-6, IL-17, and IL-1β in epithelial and immune cells of the colonic mucosa.
Expansion of Treg Cells
Increase in CD4+CD25+FoxP3+ (regulatory T cells) in the lamina propria → local immunological tolerance and prevention of relapses.
Restoration of the Mucosal Barrier
Increased expression of occludin and claudin-1 (tight junction proteins) → reduction of intestinal permeability and inflammatory recruitment.
Scientific Evidence
Acupuncture in UC has been studied in randomized clinical trials conducted in China and Europe, focusing on objective clinical outcomes (Mayo Score, mucosal remission) and inflammatory biomarkers in colonic biopsy tissue.
Gut 2020 Study — Multicenter RCT (n=149)
World J Gastroenterol 2018 Study — Colonic Biopsy (n=93)
Modern Approach: Integrative Medical Acupuncture
The integration of acupuncture into UC management follows an evidence-based protocol, with precise indications of points, frequency, and joint clinical monitoring with gastroenterology. The goal is to broaden the response to conventional treatment — not to replace it.
ELECTROACUPUNCTURE PROTOCOL IN UC
| PARAMETER | STANDARD PROTOCOL | NOTE |
|---|---|---|
| Main points | Bilateral ST25 + bilateral ST36 | Core of the protocol (based on RCTs) |
| Auxiliary points | LI11 + BL25 | Additional immunological modulation |
| EA frequency | 25 Hz (dense-disperse) | Anti-inflammatory and pro-motility |
| Session duration | 30 minutes | Standard in published RCTs |
| Weekly frequency | 3 sessions / week | Active phase / induction |
| Initial cycle | 10–12 weeks | Assessment with Mayo Score at the end |
| Maintenance | 1–2 sessions / month | In stable clinical remission |
When to See a Medical Acupuncturist
Main Indications
- UC in remission for relapse prevention
- Residual symptoms even in endoscopic remission
- Quality of life compromised by anxiety or pain
- Corticosteroid dependence — adjuvant in the tapering strategy conducted by the gastroenterologist
- Intolerance or adverse effects to medications
Situations Requiring Caution
- Acute flare: prioritize pharmacological treatment first
- High fever + abrupt worsening: rule out toxic megacolon
- Severe immunosuppression: rigorous asepsis required
- Anticoagulation: inform for technique adjustment
Frequently Asked Questions
Frequently Asked Questions
No. Acupuncture is an adjuvant treatment — it complements but does not replace mesalazine (5-ASA), azathioprine, anti-TNF agents (infliximab, adalimumab), vedolizumab, JAK inhibitors, or corticosteroids at prescribed doses. Never interrupt or reduce IBD medications without guidance from the gastroenterologist — inadvertent discontinuation can trigger a severe acute flare. The goal of acupuncture is to complement conventional treatment and contribute to quality of life.
Most studies observe clinical improvement starting at the 4th to 6th session. An initial cycle of 10 to 12 weeks (3 sessions/week) is recommended for response evaluation. In stable remission, monthly maintenance sessions are usually sufficient.
Yes. There are no known interactions between acupuncture and biologics. In immunosuppressed patients, the medical acupuncturist adopts reinforced asepsis precautions — sterile disposable needles and rigorous skin antisepsis — to minimize any infectious risk.
Yes. Adapted techniques with finer needles, shallower depth, and briefer stimulation are used in pediatric patients. Consent from the guardians, prior pediatric evaluation, and the physician's experience in pediatrics are essential.
The typical sensation (deqi) is one of pressure, heaviness, or mild tingling — rarely described as sharp pain. Electroacupuncture adds low-intensity current that causes painless rhythmic muscle contraction. Sessions last 30 minutes with the patient in comfortable rest.
Related Articles
Modulation of transmural inflammation in IBD
Acupuncture for Functional DyspepsiaNormalization of gastric emptying
Acupuncture for Intestinal ConstipationCONSTIPATE trial Lancet 2020: level 1 evidence
Acupuncture for Functional Abdominal PainVisceral hyperalgesia and the gut-brain axis